GordanaVlahovicMD

Clinical Trials

• Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01

  Terminated

  Phase 2

• Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia Start of enrollment: 2007 Apr 24

  Completed

  Phase 1

• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Feb 06

  Completed

  Phase 1

• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2007 Sep 01

  Completed

  Phase 2

• Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer Start of enrollment: 2008 Sep 01

  Completed

  Phase 1

• Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme Start of enrollment: 2009 Sep 01

  Completed

  Phase 1

• Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma Start of enrollment: 2014 Jan 09

  Terminated

  Phase 1, Phase 2

• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07

  Active, not recruiting

  Phase 3

• Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 Start of enrollment: 2004 Nov 01

  Terminated

  Phase 1, Phase 2

• IDH1 Peptide Vaccine for Recurrent Grade II Glioma Start of enrollment: 2016 Jan 28

  Completed

  Phase 1

• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01

  Completed

  Phase 1, Phase 2

• EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma Start of enrollment: 2017 Feb 01

  Terminated

  Phase 1

• PVSRIPO in Recurrent Malignant Glioma Start of enrollment: 2017 Jun 01

  Active, not recruiting

  Phase 2

• Join now to see all